铂类抗肿瘤药物研究进展被引量：11

Development of platinum antineoplastic agents

导出

摘要奈达铂、奥沙利铂等新型铂类抗肿瘤药物在临床上广泛应用，其具有抗癌谱广、活性强、不良反应低、与顺铂无交叉耐药性等特点。此外，尚处于临床研究中的亲脂性铂配合物、多核铂配合物等新型铂类化合物，也显示出提高疗效、降低不良反应的优势。目前的研究主要是通过改良顺铂、卡铂的结构和探索结构全新的铂类化合物，以达到提高患者生活质量、延长生存时问的目的。铂类化合物在细胞毒药物中仍然占有重要的地位和良好的应用前景。 Nedaplatin and oxaliplatin are widely used in clinic as new antineoplastic agents against a broad spectrum of solid tumors, which arc characterized by broader anticancer spectrum, higher activity and less toxicity, especially no cross resistance with cisplatin. In addition, the lipophilic platinum compound, the muhinuclear platinum compound and others are being still clinically tested, which also show the advantages of high efficacy and low toxicity. Current researches are mainly focus on reforming the structure of cisplatin and carboplatin, and exploring platinum compounds with totally new structure to improve quality of life and prolonging survival time of patients. Platinum compounds still have exceedingly vital position and satisfactory application perspective in cytotoxic drugs.

作者叶瑞萍杨扬(综述) 陈振东(审校)

机构地区安徽医科大学第一附属医院肿瘤内科

出处《国际肿瘤学杂志》 CAS 2008年第9期674-677,共4页 Journal of International Oncology

关键词抗肿瘤药铂化合物肿瘤 Antineoplastie agents Platinum compounds Neoplasms

分类号 R9 [医药卫生—药学]

引文网络
相关文献

参考文献21

1Matsumoto H, Hirai T, Hirabayashi Y, et al. A feasible study of docetaxel/nedaplatin combined chemotherapy for relapsed or refractory esophageal cancer patients as a 2nd-line chemotherapy. Gan To Kagaku Ryoho, 2007, 34(5):725-728.
2Mauer AM, Kraut EH, Krauss SA, et al. Phase Ⅱ trial of oxaliplatin, leucovorin and fluorouracil in patients with advanced carcinoma of the esophagus. Ann Oncol, 2005, 16(8) :1320-1325.
3Fu S, Kavanagh J J, Hu W, et at. Clinical application of oxaliplatin in epithelial ovarian cancer. Int J Gyneeol C aneer, 2006,16 (5) : 1717- 1732.
4Arkenau HT, Graeven U, Kubicka S, et al. Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clin Colorectal Cancer, 2008,7 ( 1 ) :60-64.
5Gamelin L, Boisdron- Celle M, Morel A, et at. Oxaliplatin neurotoxicity. Bull Cancer, 2006,93 Suppl 1 :S17-22.
6Min YJ, Bang SJ, Shin JW, et al. Combination chemotherapy with 5- fluorouracil and heptaplatin as first-line treatment in patients with advanced gastric cancer. J Korean Med Sci, 2004,19 (3) :369-373.
7Lee JW, Park JK, Lee SH, et al. Anti-tumor activity of heptaplatin in eombination with 5-fluorouraeil or paelitaxel against human head and neck cancer cells in vitro. Anticancer Drugs, 2006,17 (4) :377- 384.
8Galanski M, Jakupec MA, Keppler BK. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr Med Chem, 2005,12 ( 18 ) : 2075 -2094.
9Choy H. Satraplatin : an orally available platinum analog for the treatment of cancer. Expert Rev Anticancer Ther, 2006, 6(7) :973-982.
10Wosikowski K, Larnphere L, Unteregger G, et al. Preclinical antitumor activity of the oral platinum analog satraplatin. Cancer Chemother Pharmacol, 2007,60(4) :589-600.